Industry
VSL Pharmaceuticals
Total Trials
6
Recruiting
0
Active
0
Completed
3
Success Rate
50.0%-37% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
Failure Rate
50.0%
3 terminated/withdrawn out of 6 trials
Success Rate
50.0%
-36.5% vs industry average
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
N/A
3(50.0%)
Phase 1
1(16.7%)
Phase 2
1(16.7%)
Phase 3
1(16.7%)
6Total
N/A(3)
Phase 1(1)
Phase 2(1)
Phase 3(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (6)
Showing 6 of 6 trials
NCT03415711Not ApplicableTerminated
PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis
Role: lead
NCT01701297Phase 2Terminated
VSL#3 and Spontaneous Bacterial Peritonitis
Role: collaborator
NCT00944736Phase 3Completed
Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease
Role: collaborator
NCT01241201Not ApplicableCompleted
Intestinal Barrier Function and Probiotics.
Role: collaborator
NCT00099723Phase 1Terminated
The Effect of a Probiotic on Hepatic Steatosis
Role: lead
NCT00951548Not ApplicableCompleted
Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative Colitis
Role: lead
All 6 trials loaded